To include your compound in the COVID-19 Resource Center, submit it here.

Bach: Part B change could stem price hikes, hurt oncologists

In a Memorial Sloan Kettering Cancer Center.

The report said the proposed reimbursement change could dissuade manufacturers from raising prices because the payment rate for infused drugs is

Read the full 288 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE